This has reference to our letter dated January 16 2025. 1) The Board has considered and approved the unaudited Consolidated & Standalone Financial Results of the company, for the Quarter ended 31.12.2024 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015. 2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2024 has also been approved. 3) The Board has discussed and approved a funding proposal to raise funds on a securitized basis to address the pressing demands on the company and passed appropriate resolution to move the proposal forward. The meeting commenced at 11:00 a.m. and concluded at 12:25 p.m.

pdf

Transgene Biotek Ltd.

20 Jan 2025

Company Update

TRANSGENE BIOTEK LTD. - 526139 - Statement Of Deviation & Variation

BSE India

Statement of Deviation & Variation

pdf

Transgene Biotek Ltd.

20 Jan 2025

Company Update

TRANSGENE BIOTEK LTD. - 526139 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Compliances Certificate under Reg. 74(5) of SEBI

pdf

Transgene Biotek Ltd.

16 Jan 2025

Board Meeting

TRANSGENE BIOTEK LTD. - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting To …

BSE India

TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve 1. To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended December 31, 2024.Along with (Standalone & Consolidated) Limited review report thereon. 2. To transact such other business as may be required.

pdf